John G Ullman & Associates Inc. cut its position in Johnson & Johnson (NYSE:JNJ) by 22.6% during the third quarter, according to its most recent filing with the SEC. The fund owned 198,257 shares of the company’s stock after selling 58,052 shares during the period. Johnson & Johnson comprises 4.8% of John G Ullman & Associates Inc.’s portfolio, making the stock its largest position. John G Ullman & Associates Inc.’s holdings in Johnson & Johnson were worth $23,420,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Bank of Montreal Can acquired a new stake in shares of Johnson & Johnson during the second quarter worth about $858,505,000. Emerald Acquisition Ltd. acquired a new stake in shares of Johnson & Johnson during the second quarter worth about $805,455,000. Vanguard Group Inc. boosted its stake in shares of Johnson & Johnson by 2.2% in the second quarter. Vanguard Group Inc. now owns 184,512,652 shares of the company’s stock worth $22,381,384,000 after buying an additional 3,924,090 shares during the last quarter. BlackRock Fund Advisors boosted its stake in shares of Johnson & Johnson by 5.5% in the second quarter. BlackRock Fund Advisors now owns 42,089,045 shares of the company’s stock worth $5,105,401,000 after buying an additional 2,192,319 shares during the last quarter. Finally, Capital World Investors boosted its stake in shares of Johnson & Johnson by 10.3% in the second quarter. Capital World Investors now owns 22,025,323 shares of the company’s stock worth $2,671,672,000 after buying an additional 2,050,323 shares during the last quarter. 64.13% of the stock is currently owned by institutional investors.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) traded down 0.83% during trading on Monday, reaching $113.18. 4,439,608 shares of the company were exchanged. Johnson & Johnson has a 1-year low of $94.28 and a 1-year high of $126.07. The stock has a market capitalization of $307.91 billion, a P/E ratio of 19.87 and a beta of 0.75. The company’s 50-day moving average price is $116.14 and its 200-day moving average price is $118.35.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 18th. The company reported $1.68 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.66 by $0.02. Johnson & Johnson had a net margin of 22.03% and a return on equity of 25.30%. The business had revenue of $17.80 billion for the quarter, compared to analyst estimates of $17.71 billion. During the same quarter in the prior year, the business posted $1.49 EPS. Johnson & Johnson’s revenue for the quarter was up 4.2% compared to the same quarter last year. On average, equities analysts forecast that Johnson & Johnson will post $6.72 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 6th. Shareholders of record on Tuesday, November 22nd will be paid a dividend of $0.80 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.29. The ex-dividend date of this dividend is Friday, November 18th. This represents a $3.20 dividend on an annualized basis and a yield of 2.80%. Johnson & Johnson’s dividend payout ratio is presently 56.64%.

ILLEGAL ACTIVITY WARNING: “John G Ullman & Associates Inc. Has $23,420,000 Stake in Johnson & Johnson (JNJ)” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another website, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be read at https://www.thecerbatgem.com/2016/11/28/john-g-ullman-associates-inc-has-23420000-stake-in-johnson-johnson-jnj.html.

A number of brokerages have issued reports on JNJ. Argus reissued a “buy” rating and set a $145.00 target price on shares of Johnson & Johnson in a report on Friday, October 21st. Vetr cut shares of Johnson & Johnson from a “buy” rating to a “hold” rating and set a $119.60 target price on the stock. in a report on Tuesday, November 1st. Leerink Swann reissued a “buy” rating on shares of Johnson & Johnson in a report on Sunday, September 11th. Jefferies Group boosted their target price on shares of Johnson & Johnson from $113.00 to $119.00 and gave the company a “hold” rating in a report on Thursday, August 4th. Finally, Societe Generale reaffirmed a “hold” rating and issued a $116.00 price target on shares of Johnson & Johnson in a report on Sunday, October 23rd. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the company’s stock. Johnson & Johnson presently has a consensus rating of “Hold” and a consensus price target of $121.02.

In related news, Director Charles Prince purchased 875 shares of the business’s stock in a transaction on Friday, October 21st. The shares were acquired at an average price of $114.11 per share, for a total transaction of $99,846.25. Following the purchase, the director now owns 26,520 shares of the company’s stock, valued at approximately $3,026,197.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 0.11% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.